23 May 2013
Keywords: Novo Nordisk, Vatreptacpg, Hemophilia, Ph III, Discontinued
Article | 30 September 2012
Danish insulin giant Novo Nordisk (NOV: N) says that it has decided to discontinue the development of vatreptacog alfa, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 September 2012
1 October 2012
© 2013 thepharmaletter.com